Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IK-930 |
Synonyms | |
Therapy Description |
IK-930 inhibits TEAD, potentially leading to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2022) 82 (12_Supplement): 2156). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IK-930 | IK 930|IK930 | IK-930 inhibits TEAD, potentially leading to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2022) 82 (12_Supplement): 2156). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | GBR | AUS | 0 |